Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Han, Han ^a,b   Yang, Xiaojing ^b   Pandiyan, Kurinji ^b,c   Liang, Gangning ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; CLORGYLINE; DNA; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEMETHYLASE; INTERFERON; LYSINE SPECIFIC DEMETHYLASE 1; UNCLASSIFIED DRUG; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; ENZYME INHIBITOR; HISTONE; KDM1A PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL TYPE; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DNA MODIFICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EPIGENETICS; GENE REACTIVATION; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DNA METHYLATION; DRUG EFFECTS; METABOLISM; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

AZACITIDINE; CELL LINE, TUMOR; CLORGYLINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG SYNERGISM; ENZYME INHIBITORS; GENE SILENCING; HISTONE DEMETHYLASES; HISTONES; HUMANS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84883647864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075136     Document Type: Article

References (46)

1. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128: 683-692.
2. Kelly TK, De Carvalho DD, Jones PA, (2010) Epigenetic modifications as therapeutic targets. Nat Biotechnol 28: 1069-1078.
3. Boumber Y, Issa JP (2011) Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220-226, 228.
4. Hebbes TR, Thorne AW, Crane-Robinson C, (1988) A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 7: 1395-1402.
5. Kouzarides T, (2007) Chromatin modifications and their function. Cell 128: 693-705.
6. Liang G, Lin JC, Wei V, Yoo C, Cheng JC, et al. (2004) Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A 101: 7357-7362.
7. Sharma S, Kelly TK, Jones PA, (2010) Epigenetics in cancer. Carcinogenesis 31: 27-36.
8. Kubicek S, Jenuwein T, (2004) A crack in histone lysine methylation. Cell 119: 903-906.
9. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, et al. (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953.
10. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
11. You A, Tong JK, Grozinger CM, Schreiber SL, (2001) CoREST is an integral component of the CoREST- human histone deacetylase complex. Proc Natl Acad Sci U S A 98: 1454-1458.
12. Shi Y, Sawada J, Sui G, Affar el B, Whetstine JR, et al. (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422: 735-738.
13. Hakimi MA, Bochar DA, Chenoweth J, Lane WS, Mandel G, et al. (2002) A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc Natl Acad Sci U S A 99: 7420-7425.
14. Kooistra SM, Helin K, (2012) Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 13: 297-311.
15. Lokken AA, Zeleznik-Le NJ, (2012) Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Cancer Cell 21: 451-453.
16. Wang J, Hevi S, Kurash JK, Lei H, Gay F, et al. (2009) The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 41: 125-129.
17. Nicholson TB, Chen T, (2009) LSD1 demethylates histone and non-histone proteins. Epigenetics 4: 129-132.
18. Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, et al. (2008) A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7: 2019-2027.
19. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, et al. (2009) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69: 2065-2071.
20. Lim S, Janzer A, Becker A, Zimmer A, Schule R, et al. (2010) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31: 512-520.
21. Hayami S, Kelly JD, Cho HS, Yoshimatsu M, Unoki M, et al. (2011) Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer 128: 574-586.
22. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, et al. (2012) The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21: 473-487.
23. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP, (2011) Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nature structural & molecular biology 18: 867-874.
24. Zhao H, Flamand V, Peehl DM, (2009) Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics 2: 55.
25. Kauffman EC, Robinson BD, Downes MJ, Powell LG, Lee MM, et al. (2011) Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog 50: 931-944.
26. Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, et al. (2012) Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 42: 887-898.
27. Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, et al. (2011) Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol 42: 1667-1675.
28. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, et al. (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436-439.
29. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
30. Jones PA, (2002) DNA methylation and cancer. Oncogene 21: 5358-5360.
31. Jones PA, Taylor SM, (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93.
32. Quintas-Cardama A, Santos FP, Garcia-Manero G, (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25: 226-235.
33. Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD, et al. (1999) Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 19: 6690-6698.
34. Yang X, Noushmehr H, Han H, Andreu-Vieyra C, Liang G, et al. (2012) Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet 8: e1002604.
35. Egger G, Jeong S, Escobar SG, Cortez CC, Li TW, et al. (2006) Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. Proc Natl Acad Sci U S A 103: 14080-14085.
36. Bennani-Baiti IM, Machado I, Llombart-Bosch A, Kovar H, (2012) Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol 43: 1300-1307.
37. Schenk T, Chen WC, Gollner S, Howell L, Jin L, et al. (2012) Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18: 605-611.
38. Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, et al. (2009) Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 15: 7217-7228.
39. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, et al. (2007) p53 is regulated by the lysine demethylase LSD1. Nature 449: 105-108.
40. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T, (2002) Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res 62: 961-966.
41. Akers SN, Odunsi K, Karpf AR, (2010) Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol 6: 717-732.
42. Karpf AR, (2006) A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 1: 116-120.
43. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ, (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5: 615-625.
44. Dunn GP, Koebel CM, Schreiber RD, (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
45. Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, et al. (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17: 2619-2627.
46. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, et al. (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336.